Lubaina Haider, Sara Sharif, Abida Hasan and Isabel M. McFarlane. Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury.
. 2020; 8(7):206-209. doi: 10.12691/AJMCR-8-7-12
rheumatoid arthritis, methotrexate, leucovorin, acute kidney injury, pancytopenia, delayed excretion, vancomycin
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176. |
|
[2] | Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 1982; 100: 314. |
|
[3] | Allegra CJ, Grem JL. Antimetabolites. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practices of Oncology, 5th edition. Philadelphia: Lippincott-Raven 1997; 432-465. |
|
[4] | Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29: 822. |
|
[5] | McEvoy G (ed.) Methotrexate. In: American Hospital Formulary Service 2000. Bethesda: American Society of Health System Pharma- cists 2000; 1011-1019. |
|
[6] | Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433. |
|
[7] | Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis 2016. |
|
[8] | Giuliano CA, Patel CR, Kale-Pradhan PB. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy 2016; 36: 1217. |
|
[9] | Blum R, Seymour JF, Toner G. Significant impairment of high dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Annals of Oncology 13: 327-330, 2002. |
|
[10] | Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82. |
|
[11] | Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18. |
|
[12] | King, D.W. & Smith, M.A. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol. Vitro. 18, 797-803 (2004). |
|
[13] | Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 138-141. |
|
[14] | Luque, Y. et al. Vancomycin-associated cast nephropathy. J. Am. Soc. Nephrol. 2017. |
|
[15] | S. Karie, F. Gandjbakhch, N. Janus et al., “Kidney disease in RA patients: prevalence and implications of RA-related drugs management: the MATRIX study,” Rheumatology, vol. 47, no. 3, pp. 350-354, 2008. |
|
[16] | Shaikh N, Sardar M, Raj R, et al. A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity. Case Reports in Medicine Hindawi, vol. 2018, Article ID 9056086, 4 pages. |
|
[17] | J. A. Singh, K. G. Saag, S. L. Bridges et al., “2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis,” Arthritis Care and Research, vol. 68, no. 1, pp. 1-25, 2016. |
|
[18] | S. C. Howard, J. McCormick, C. H. Pui, R. K. Buddington, and R. D. Harvey, “Preventing and managing toxicities of high dose methotrexate,” Oncologist, vol. 21, no. 12, pp. 1471-1482, 2016. |
|
[19] | Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. The Oncologist 2006; 11:694-703. |
|